TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23698171
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) by auxiliaries
Study: 19188683
Drug: Mitochondrial-targeted antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitochondrial-targeted antioxidant treatment in rats
Study: 17211305
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg of isobaric bupivacaine with 20 microgr fentanyl
Study: 17211305
Drug: 13.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13.5 mg of standardized isobaric 0.5% bupivacaine
Study: 12776641
Drug: Inhaled isopropyl
Normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled isopropyl alcohol (70%)
Study: 10671913
Drug: Health authority/pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health authority/pharmaceutical company collaborative intervention
Study: 3007219
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (open biopsy, resection, excision)
Study: 3231285
Drug: Overall surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall surgical treatment
Study: 3007219
Drug: Post-operative chemotherapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative chemotherapy
Study: 23394509
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled corticosteroids (ICSs) at doses of two, four, or eight times their maintenance ICS dose for 12 days
Study: 23394509
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the maintenance dose of ICS
Study: 18395165
Drug: Statin-fibrate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin-fibrate therapy (control)
Study: 12645393
Drug: Selegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (10 mg/die for six months)
Study: 9583927
Drug: Aminosidine 12
Normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminosidine 12 mg/kg/day for 21 days
Study: 9583927
Drug: Aminosidine 16
Normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminosidine 16 mg/kg/day for 21 days
Study: 9583927
Drug: Aminosidine 20
Normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminosidine 20 mg/kg/day for 21 days
Study: 9583927
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 20 mg/kg/day for 30 days
Study: 9583927
Drug: Aminosidine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminosidine (16 and 20 mg/kg/day)
Study: 30256277
Drug: Mindfulness meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness meditation (daily practice for 21 days)
Study: 20559255
Drug: Viferon gel
Normalized name: Uniferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viferon gel (0.5 ml, 4-5 times daily)
Study: 8523654
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no PGE1 administration)
Study: 6218964
Drug: Depo-medroxyprogesterone acetate
Normalized name: medroxyprogesterone Injection [Depo-Provera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-medroxyprogesterone acetate (DMPA) administered on cycle day 5
Study: 6218964
Drug: Depo-medroxyprogesterone acetate
Normalized name: medroxyprogesterone Injection [Depo-Provera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-medroxyprogesterone acetate (DMPA) administered on cycle day 7
Study: 6218964
Drug: Depo-medroxyprogesterone acetate
Normalized name: medroxyprogesterone Injection [Depo-Provera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-medroxyprogesterone acetate (DMPA) administered on cycle day 9
Study: 6218964
Drug: Depo-medroxyprogesterone acetate
Normalized name: medroxyprogesterone Injection [Depo-Provera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-medroxyprogesterone acetate (DMPA) administered on cycle day 11
Study: 25500669
Drug: Vapor ablation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapor ablation therapy targeting the most diseased segments of the lung, specific dosage and duration not mentioned.
Study: 22840278
Drug: C+P (behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+P (behavioral counseling and education followed by monthly phone calls for 6 months)
Study: 17664469
Drug: ECF (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECF (epirubicin 50 mg/m(2) on day 1, cisplatin 60 mg/m(2) on day 1, and fluorouracil 200 mg/m(2)/d on days 1 to 21)
Study: 17664469
Drug: TC (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC (docetaxel initially 85 mg/m(2) on day 1, later reduced to 75 mg/m(2), and cisplatin 75 mg/m(2) on day 1)
Study: 17664469
Drug: TCF (TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCF (TC plus FU 300 mg/m(2)/d on days 1 to 14)
Study: 2246915
Drug: Low-dose sotalol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sotalol (40 mg every 8 hours)
Study: 2246915
Drug: Low-dose propranolol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propranolol (10 mg every 6 hours)
Study: 2246915
Drug: High-dose sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sotalol (80 mg every 8 hours)
Study: 2246915
Drug: High-dose propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose propranolol (20 mg every 6 hours)
Study: 2246915
Drug: High-dose sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sotalol
Study: 2246915
Drug: Low-dose propranolol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propranolol
Study: 2246915
Drug: High-dose propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose propranolol
Study: 6818684
Drug: Ordinary cow
Normalized name: Cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary cow milk (lactose content, 25 g)
Study: 29092881
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride (KCl) supplements, 40 mEq/d for 3 months
Study: 24922046
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of rosuvastatin for 6 weeks before carotid artery stenting (CAS)
Study: 18258584
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care and rinses
Study: 12805333
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) with autologous stem-cell transplantation (ASCT)
Study: 11205467
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) with ASCT (in patients < 65 years)
Study: 11205467
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (in patients < 65 years)
Study: 9084194
Drug: Topical doxymycine
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical doxymycine
Study: 8366182
Drug: Didanosine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 300 mg chewable tablet after overnight fast
Study: 8366182
Drug: Didanosine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 300 mg chewable tablet 30 minutes before a meal
Study: 8366182
Drug: Didanosine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 300 mg chewable tablet 1 hour before a meal
Study: 8366182
Drug: Didanosine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 300 mg chewable tablet 1 hour after a meal
Study: 8366182
Drug: Didanosine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 300 mg chewable tablet 2 hours after a meal
Study: 30647044
Drug: BDD-NET (therapist-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDD-NET (therapist-guided internet-based cognitive behavioural therapy)
Study: 28306389
Drug: Inclisiran (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (200 mg, 300 mg, 500 mg single dose)
Study: 28306389
Drug: Inclisiran (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (100 mg, 200 mg, 300 mg two doses at days 1 and 90)
Study: 28306389
Drug: Inclisiran (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (300 mg two doses)
Study: 25326088
Drug: Guidelines on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guidelines on treatment of RTIs and uncomplicated lower UTIs with sustained, regular feedback on individual antibiotic prescription behaviour during 2 years
Study: 22965965
Drug: Cediranib 20
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 20 mg plus FOLFOX/CAPOX
Study: 19006537
Drug: Lubiprostone 8
Normalized name: LUBIPROSTONE 8MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 8 mcg twice daily
Study: 2825469
Drug: Naloxone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (6 mg/kg)
Study: 29292242
Drug: ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticagrelor 90 mg twice daily
Study: 29292242
Drug: prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: prasugrel 10 mg once daily
Study: 23963690
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) soybean, olive oil, and fish oil emulsion
Study: 23963690
Drug: Parenteral soybean
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral soybean and olive oil emulsion (control)
Study: 22390886
Drug: Internet-delivered physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered physical activity and healthy nutrition program with monthly email messages and additional web-based tools.
Study: 22390886
Drug: Monthly email
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly email messages to promote website visits during the first year.
Study: 20869041
Drug: 20-week treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-week treatment for BED
Study: 16027343
Drug: Injected hyaluronidase
Normalized name: hyaluronidase Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected hyaluronidase (3 different doses)
Study: 30516416
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text message reminders (N = 42)
Study: 30516416
Drug: Weekly text
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly text message reminders (N = 37)
Study: 27040362
Drug: Low non-HDL-C
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low non-HDL-C level (≤140 mg/dl)
Study: 27040362
Drug: Low cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low cholesterol group (≤140 mg/dl)
Study: 25130584
Drug: Tadalafil (phosphodiesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (phosphodiesterase enzyme-5 inhibitor)
Study: 15860392
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg/day for 3 days
Study: 11939924
Drug: Ropivacaine 2
Normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2 mg/mL with sufentanil 0.75 microg/mL
Study: 11939924
Drug: Bupivacaine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 1.25 mg/mL with sufentanil 0.75 microg/mL
Study: 2572140
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cetirizine nocte
Study: 2572140
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg terfenadine given morning and evening
Study: 1096829
Drug: Agar (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agar (600 mg/kg daily for 7 days, starting at 12 hours of age)
Study: 1096829
Drug: Agar (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agar (700 mg/kg daily for 7 days, starting at 6 hours of age)
Study: 28851329
Drug: Additional daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional daily school-time physical activity (PA)
Study: 25344064
Drug: Intravenous dantrolene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dantrolene (IV‐D) 1.25 mg every 6 hours for 7 days (n=16)
Study: 20110024
Drug: Etizolam 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etizolam 0.5 mg BID
Study: 17007849
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg anastrozole for 5 days (cycle days 3‐7) followed by FSH injections (days 7‐11)
Study: 17007849
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg clomiphene citrate for 5 days (cycle days 3‐7) followed by FSH injections (days 7‐11)
Study: 17007849
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg clomiphene citrate
Study: 15503077
Drug: Total daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily energy expenditure (TEE)
Study: 10709155
Drug: Cetrorelix (CET)
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix (CET) 3 mg intravenously (IV)
Study: 10709155
Drug: Cetrorelix (CET)
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix (CET) 3 mg subcutaneously (SC)
Study: 10709155
Drug: Cetrorelix (CET)
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix (CET) 3 mg IV
Study: 10709155
Drug: Cetrorelix (CET)
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix (CET) 3 mg SC
Study: 10709155
Drug: Cetrorelix (CET)
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix (CET) 3 mg IV and SC
Study: 1547881
Drug: Single-agent interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent interferon (IFN)-alpha at an initial dose of 4 x 10(6) U/m2 (arm A)
Study: 1547881
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IFN-alpha and low-dose IFN-gamma (arm B)
Study: 28586116
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplant (FMT) with 5 days of broad-spectrum antibiotic pretreatment and a single FMT enema from the same donor.
Study: 18444793
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of metronidazole plus 150 mg of fluconazole
Study: 14979636
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (200 mg for children ≤ 7 years, 290 mg for children > 7 years)
Study: 14979636
Drug: Placebo (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (260 mg glucose)
Study: 10907966
Drug: Heparin (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (30, 60, 120, or 240 U/kg bolus)
Study: 10907966
Drug: Heparin (0.15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (0.15, 0.20, 0.25, or 0.30 U/kg/minute with or without a 125-U/kg bolus)
Study: 10907966
Drug: Argatroban (250-microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (250-microg/kg bolus plus infusion of 15, 20, 30, and 40 microg/kg/minute)
Study: 8698954
Drug: Naltrexone (opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (opioid receptor blockade)
Study: 4005391
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg (repeated dose)
Study: 31087536
Drug: Fluconazole with
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole with a loading dose of 25 mg/kg
Study: 31087536
Drug: Fluconazole without
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole without specified loading dose
Study: 30336850
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg kg-1 then 4 mg kg-1 h-1)
Study: 30336850
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine and saline
Study: 27615041
Drug: Inhalation breathing
Normalized name: beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation breathing exercises using incentive spirometry (Control)
Study: 22309470
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management in combination with family engagement strategies (CM-FAM)
Study: 12404080
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) patches (21 mg/24 h)
Study: 12404080
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) patches
Study: 9454908
Drug: L-arginine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (30 g/day for three days)
Study: 1710743
Drug: Bezafibrate (Bezalip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (Bezalip Mono) 400 mg once daily
Study: 29743827
Drug: Carbohydrate mouth
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate mouth rinse (CMR) with a 6% unflavored maltodextrin solution
Study: 26246020
Drug: Polysoft patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysoft patch (PP)
Study: 26246020
Drug: Modified Kugel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Kugel patch (MK)
Study: 22892729
Drug: 1-visit treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-visit treatment
Study: 22892729
Drug: 2-visit treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-visit treatment
Study: 15842552
Drug: Gentamicin delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin delivered orally (80 mg)
Study: 15842552
Drug: Gentamicin delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin delivered intravenously (40 mg)
Study: 15842552
Drug: Aerodynamic characteristics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerodynamic characteristics of nebulized doses from PARI
Study: 15842552
Drug: Aerodynamic characteristics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerodynamic characteristics of nebulized doses from MN
Study: 11932273
Drug: E/A group
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/A group (1.25 mg estrogen + 2.5 mg methyltestosterone/d)
Study: 11932273
Drug: E group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: E group (1.25 mg/d)
Study: 3276201
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of estradiol valerate topical gel
Study: 3276201
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of prostaglandin E2 gel
Study: 3276201
Drug: Placebo prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo prostaglandin E2 dosage
Study: 25001158
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 0.5 mg bevacizumab
Study: 26644132
Drug: Reinforcement‐based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcement‐based Treatment plus Women's Co‐Op (RBT + WC)
Study: 20140405
Drug: Cognitive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive treatment of illness perceptions
Study: 18542921
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume hemofiltration (HVHF 65 ml/(kg h))
Study: 18542921
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume hemofiltration (LVHF 35 ml/(kg h))
Study: 9537146
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia with a van Lint block
Study: 19938160
Drug: CC genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC genotype
Study: 22353457
Drug: Glass ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass ionomer sealants with tooth preparation
Study: 22353457
Drug: Resin sealants
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin sealants with tooth preparation
Study: 22353457
Drug: Glass ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass ionomer sealants without tooth preparation
Study: 22353457
Drug: Resin sealants
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin sealants without tooth preparation
Study: 22353457
Drug: Tooth preparation
Normalized name: porcine tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth preparation
Study: 22353457
Drug: Glass ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass ionomer sealants without preparation
Study: 16076991
Drug: High dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dairy diet (1200 mg Ca/d, 3 servings of dairy)
Study: 16076991
Drug: Low dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dairy diet (500 mg/d, <1 serving/d)
Study: 16076991
Drug: High dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dairy diet (1200 mg Ca/d, 3 servings of dairy) with caloric restriction (‐500 kcal/d)
Study: 16076991
Drug: Low dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dairy diet (500 mg/d, <1 serving/d) with caloric restriction (‐500 kcal/d)